Infectious Diseases Search
Infectious Diseases Infectious Diseases
genital%20herpes
GENITAL HERPES
Genital herpes is a recurrent lifelong disease with no cure, caused by herpes simplex virus (HSV).
HSV-2 is usually the cause but HSV-1 may occur in up to 1/3 of new cases.
HSV-1 tends to cause fewer recurrences & milder disease than HSV-2.
The incubation period is 2 days-2 weeks after exposure.

Genital%20herpes Signs and Symptoms

Introduction

  • Recurrent lifelong disease with no cure, caused by herpes simplex virus (HSV)
  • Typically occurs in adults, usually transmitted through sexual contact 
  • Incubation period is 2 days-2 weeks after exposure

Etiology

Herpes Simplex Virus (HSV)
  • HSV-1: Tends to cause fewer recurrences and milder disease than HSV-2
  • HSV-2: Usually the cause of genital herpes but HSV-1 may occur in up to 1/3 of new cases

Risk Factors

Risk Factors for Genital Herpes Simplex Virus Infection
  • Multiple sexual partners
  • Previous history of sexually transmitted infection (STI) including HIV
  • History of genital lesion in self or partner
  • Partner diagnosed with genital HSV infection
  • Early age of 1st sexual activity (≤17 years old)
  • Female gender
  • Low socioeconomic status; low level of education
  • Advancing age
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Slight amino acid tweak weakens HBV
Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).
Pfizer and BioNTech are testing 4 novel vaccines in Europe and US.
Pank Jit Sin, 13 May 2020
A trial vaccine for the prevention of COVID-19 is underway with the first US participants being dosed in the Phase 1/2 clinical trial. Known as the BNT162 vaccine programme, the trials are a collaboration between Pfizer Inc. and BioNTech SE, and is part of a global development programme with Germany and the US taking the lead in having the first cohorts to be vaccinated. Germany started the study 1 week earlier. 
Can gargling with mouthwash stop coronavirus from its tracks?
Jairia Dela Cruz, 18 Dec 2020
Rinsing with mouthwash that contains povidone-iodine (PI) or cetylpyridinium chloride (CPC) helps reduce SARS-CoV-2 levels in the saliva of COVID-19 patients, with the effect persisting for up to 6 hours, as shown in a study from Singapore.